Stereoselective reversal of MPTP-induced parkinsonism in the marmoset after dermal application of N-0437.

[1]  N. Quinn,et al.  The antiparkinsonian actions and pharmacokinetics of transdermal (+)‐4‐Propyl‐9‐hydroxynaphthoxazine (+ PHNO): Preliminary results , 1989, Movement disorders : official journal of the Movement Disorder Society.

[2]  M. Dubocovich,et al.  N-0437: a selective D-2 dopamine receptor agonist in in vitro and in vivo models. , 1988, European journal of pharmacology.

[3]  M. Dubocovich,et al.  The enantiomers of the D-2 dopamine receptor agonist N-0437 discriminate between pre- and postsynaptic dopamine receptors. , 1988, European journal of pharmacology.

[4]  A. Lees,et al.  SUBCUTANEOUS INFUSION OF APOMORPHINE AND LISURIDE IN THE TREATMENT OF PARKINSONIAN ON-OFF FLUCTUATIONS , 1987, The Lancet.

[5]  J. van der Weide,et al.  Pharmacological profiles of three new, potent and selective dopamine receptor agonists: N-0434, N-0437 and N-0734. , 1986, European journal of pharmacology.

[6]  J. Obeso,et al.  LISURIDE INFUSION PUMP: A DEVICE FOR THE TREATMENT OF MOTOR FLUCTUATIONS IN PARKINSON'S DISEASE , 1986, The Lancet.

[7]  F Stocchi,et al.  Problems in daily motor performances in Parkinson's disease: the continuous dopaminergic stimulation. , 1986, Journal of neural transmission. Supplementum.

[8]  R. Ljung,et al.  HIGH-DOSE INTRAVENOUS GAMMABLOBULIN: A CAUTIONARY NOTE , 1985, The Lancet.

[9]  J. Kebabian,et al.  N,N-disubstituted 2-aminotetralins are potent D-2 dopamine receptor agonists. , 1984, European journal of pharmacology.

[10]  J. Langston,et al.  Pargyline prevents MPTP-induced parkinsonism in primates. , 1984, Science.

[11]  C. Marsden,et al.  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset , 1984, Neuroscience Letters.

[12]  A. Lees,et al.  On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study. , 1984, Brain : a journal of neurology.

[13]  D. Jacobowitz,et al.  A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[14]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[15]  C. Marsden,et al.  COMPLICATED RESPONSE FLUCTUATIONS IN PARKINSON'S DISEASE: RESPONSE TO INTRAVENOUS INFUSION OF LEVODOPA , 1982, The Lancet.

[16]  Sanford P. Markey,et al.  Chronic parkinsonism secondary to intravenous injection of meperidine analogues , 1979, Psychiatry Research.

[17]  J. D. Parkes,et al.  "ON-OFF" EFFECTS IN PATIENTS WITH PARKINSON'S DISEASE ON CHRONIC LEVODOPA THERAPY , 1976, The Lancet.

[18]  S. Shapiro.  ALLOPURINOL AND BONE-MARROW DEPRESSION , 1974 .